SCHEMBL18702157

SCHEMBL18702157

CC(C)(C)C(=O)N1CCN(c2ncc(-c3cccc(F)c3)o2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 4/20 0.51
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
PDE4B Q07343 3/20 0.41
SCD O00767 1/20 0.41
PRKDC P78527 1/20 0.41
FAAH O00519 1/20 0.41
RIPK1 Q13546 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
PIM1 P11309 1/20 0.39
MGAM O43451 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18711523 0.89 SPR (0.53) SPRCKS1BSKP1SKP2NR4A1
SCHEMBL18702039 0.87 SPR (0.54) SPRCKS1BSKP1SKP2KMT2A
SCHEMBL18702284 0.87 SPR (0.51) SPRCKS1BSKP1SKP2TP53
SCHEMBL18702190 0.86 SPR (0.48) SPRCKS1BSKP1SKP2TP53
SCHEMBL18702283 0.85 SLC6A7 (0.47) SPRCKS1BSKP1SKP2MEN1
SCHEMBL18702194 0.82 SPR (0.50) SPRCKS1BSKP1SKP2MAPT
SCHEMBL18702036 0.80 SPR (0.47) SPRCKS1BSKP1SKP2TP53
SCHEMBL18702192 0.80 SPR (0.49) SPRCKS1BSKP1SKP2MAPT
SCHEMBL18702286 0.80 SPR (0.51) SPRCKS1BSKP1SKP2MAPT
SCHEMBL18702042 0.80 SPR (0.50) SPRCKS1BSKP1SKP2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
US-9963462-B2 Sepiapterin reductase inhibitors MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2018-05-08 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR SPR 1/4885CKS1B 3157/4885SKP1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.